image credit: Freepik

Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab

December 20, 2021


Another phase 3 study supported the efficacy of the first-in-class TSLP inhibitor as an add-on treatment for people aged 12 and over with severe asthma, as did an earlier phase 2 trial, but the miss raised questions about the drug’s approvability.

It has all come good for Amgen and AZ however, as the US regulator has approved tezepelumab –given the trade name Tezspire – as the only biologic drug for severe uncontrolled asthma that can be prescribed to all patients, and not restricted to those with specific forms of the disease.

Read More on Pharmaphorum